Article
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
BMC cancer - 14 Sept 2020
Schluckebier Luciene, Caetano Rosangela, Garay Osvaldo Ulises, Montenegro Giuliana T, Custodio Marcelo, Aran Veronica, Gil Ferreira Carlos
Abstract excerpt
BACKGROUND: The treatment of choice for advanced non-small cell lung cancer is selected according to the presence of specific alterations. Patients should undergo molecular testing for relevant modifications and the mutational status of EGFR and translocation of ALK and ROS1 are commonly tested to offer the best intervention. In addition, the tests costs should also be taken in consideration. Therefore, this work...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.